Evidence map›Paper›PMID 23877475›Full record

ReviewCurrent osteoporosis reports2013

Osteoporosis and cancer.

Matthew T Drake

Abstract readReview
In one paragraph

Review in Current osteoporosis reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it, 120 citations in OpenAlex.

  1. Falls in older adults with cancer: a systematic review of prevalence, injurious falls, and impact on cancer treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016
    Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. A multicenter prospective matched comparative study on osteoporosis risk in cancer patients receiving chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Author response to: OSIN-D-24-01898: Comment on "Association of serum alkaline phosphatase levels with bone mineral density, osteoporosis prevalence, and mortality in US adults with osteoporosis: evidence from NHANES 2005-2018".Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Utilization of Romosozumab in Primary Care.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2024
    Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Matthew T DrakeDivision of Endocrinology, Department of Medicine, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA, drake.matthew@mayo.edu.
WinnMed · US

Funding

Pathogenesis of Monoclonal Gammopathy Bone DiseaseK08AR059138 · NIAMS · MAYO CLINIC ROCHESTER · PI DRAKE, MATTHEW T · 2010 to 2014
$615k
NIAMS NIH HHS K08 AR059138
6 · The paper itself

Abstract

Cancer is a major risk factor for bone loss and fractures. This is due both to direct effects of cancer cells on the skeleton and to deleterious effects of cancer-specific therapies on bone cells. Marked improvements in survival for many cancers mean that strategies to limit bone loss and reduce fracture risk must be incorporated into the care plans for nearly all patients with cancer. The vast majority of effort thus far has focused on bone loss in patients with breast and prostate cancers, with comparatively few studies in other malignancies. Antiresorptive therapies have proven nearly universally effective for limiting bone loss in cancer patients, although few studies have been powered sufficiently to include fractures as primary endpoints, and patients are frequently neither identified nor treated according to published guidelines. Nonpharmacologic approaches to limit falls, particularly in elderly patients, are also likely important adjunctive measures for most cancer patients.

Indexed as

Bone ResorptionBreast NeoplasmsFemaleHumansIncidenceMaleNeoplasmsOsteoporosisProstatic NeoplasmsRisk Factors

Identifiers

PMID23877475
PMCPMC3783531
OpenAlexW2081197989

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.